Michael
Characterization of sialoadenitis after administration of continuous sialogogues during the day and night after 131I therapy.
byMichael
Guidelines for the indications for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations.
byMichael
Guidelines for the prescribed activity for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations.
byMichael
Whole body retention of I-131 at 24hr vs 48hr as a predictor of maximum tolerated activity.
byMichael
Alpharadin<sup>®</sup> (Xofigo<sup>®</sup>) in the treatment of skeletal metastasis secondary to metastatic prostate cancer: an educational exhibit.
byMichael
The utility of “blind” 131I treatments for differentiated thyroid cancer: an educational exhibit.
byMichael
No infographics yet
No documents yet
No likes yet
Personal Information
Organization / Workplace
MedStar Washington Hospital Center, Div of Nuclear MedicineOccupation
Research Fellow